Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Policy
Nih Finalizes Ethics Rules
Controversial rules prohibit outside consulting with biotech, pharma companies
by David J. Hanson
August 26, 2005
The National Institutes of Health has issued its final ethics regulations for all employees. The rules cover certain financial interests, stock divestiture, outside activities, and receipt of awards, but they are not as strict as regulations proposed in February (C&EN, Feb. 7, page 8).
In announcing the regulations, NIH Director Elias A. Zerhouni said, “We have a balanced set of conflict-of-interest rules that protect the integrity of NIH and its ability to provide the American public with an unbiased and trusted source of scientific and health information, while preserving our ability to recruit and retain world-class scientists and staff.”
Although the rules are substantially the same as the proposed regulations, there are some changes that have slightly eased their severity. For example, the proposed rules flatly prohibited NIH employees who are required to file financial disclosure forms from holding stock in biotechnology or pharmaceutical companies. The final rule only requires them to report their holdings. Senior employees, however, will still be held to a $15,000-per-company limit on holdings.
The final rules will permit NIH scientists to perform work for outside professional or scientific organizations, with prior approval, including serving on advisory boards and doing grant reviews. Such activities had been prohibited under the interim regulations.
The complete prohibition on outside consulting by NIH staff with pharmaceutical, biotechnology, and medical device companies remains unchanged.
The rules go into effect on Aug. 30, and NIH senior managers will have to sell stocks that pose a conflict of interest by Jan. 30, 2006.
Related Stories
Advertisement
- NIH Bans Consulting C&EN, Feb. 7, 2005
- Ethics Regulations C&EN, Feb. 21, 2005
- NIH Faces Fallout Over Ethics Rules C&EN, Apr. 11, 2005
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter